Chondroitin sulfate from sturgeon bone ameliorates pain of osteoarthritis induced by monosodium iodoacetate in rats.
Chondroitin sulfate (CS) is an important component of the extracellular matrix of cartilage and has been widely used as one of the main drugs for the treatment of joint pain-related nutraceuticals and medicines. Sturgeon bone (SB) is the main waste during deep processing of sturgeons in fishery production. The present study was evaluated the therapeutic effect of CS from SB (CSSB) on monosodium iodoacetate (MIA)-induced osteoarthritis (OA) pain and further explored the potential medicinal value of CSSB. The OA pain model was induced by intra-articular injection of MIA and then treated with CSSB. The results showed that, on the organismic level, CSSB can significantly reduce the joint swelling, reduce the pathological injury of the joints, decrease the levels of IL-1, TNF-α and PGE2 in synovial fluid, revers of hind paw support and paw withdrawal mechanical threshold decreased caused by MIA. In addition, mechanistically at the molecular level, these effects are elicited via down-regulation of the protein levels of down-regulate the protein expression of matrix metalloproteinase (MMP)-1, MMP-13 and up-regulate the protein expression of TIMP-1. These results demonstrate that CSSB can inhibit the OA pain induced by MIA, and CSSB can be used as a potential medicinal ingredient.